Effectiveness of community outreach HIV prevention programs in Vietnam: a mixed methods evaluation

Lora L. Sabin; Katherine Semrau; Mary DeSilva; Loan T T Le; Jennifer J. Beard; Davidson H. Hamer; Jordan Tuchman; Theodore M. Hammett; Nafisa Halim; Manisha Reuben; Aldina Mesic; Taryn Vian

doi:10.1186/s12889-019-7418-5

BMC Public Health

Table 5 Risky Sexual Behaviors by Intervention vs. Comparison Group and Key Population

From: Effectiveness of community outreach HIV prevention programs in Vietnam: a mixed methods evaluation

	Have ever used a condom n (%)				Among those who ever used a condom, always (100%) uses a condom n (%)				When having sex with primary partner in last 6 months, always (100%) used a condom n (%)				When having sex with casual partners in last 6 months, always (100%) used a condom n (%)				When having sex with client in last 6 months, always (100%) used a condom n (%)				Among condom users, always carries condoms n (%)
	Overall	Control Intervention	Comparison	P Value	Overall	Intervention	Comparison	P Value	Overall	Intervention	Comparison	P Value	Overall	Intervention	Comparison	P Value	Overall	Intervention	Comparison	P Value	Overall	Intervention	Comparison l	P Value
ALL	2040/2199	1044/1100	996/1099	0.004**	765/2040	421/1044	344/996	0.001**	411/1403	245/737	166/666	0.0003***	316/2199	180/1100	136/1099	0.01*	873/1370	476/681	397/689	< 0.01**	931/2040	519/1044	412/996	< 0.01**
ALL	(92.8)	(94.9)	(90.6)	0.004**	(37.5)	(40.3)	(34.5)	0.001**	(29.3)	(33.24)	(24.9)	0.0003***	(14.4)	(16.4)	(12.4)	0.01*	(63.7)	(69.9)	(57.6)	< 0.01**	(45.6)	(49.7)	(41.4)	< 0.01**
PWID (n = 694)	572/694	313/358	259/336	0.001**	179/572	108/313	71/259	0.05	88/368	57/205	31/163	0.04*	46/694	30/358	16/336	0.01*	71/128	48/78	23/50	0.09	195/572	115/313	80/259	0.16
PWID (n = 694)	(82.4)	(87.4)	(77.1)	0.001**	(31.3)	(34.5)	(27.4)	0.05	(23.9)	(27.8)	(19.0)	0.04*	(6.6)	(8.4)	(4.8)	0.01*	(55.5)	(61.5)	(46.0)	0.09	(34.1)	(36.7)	(30.9)	0.16
MSM (n = 337)	312/337	149/161	163/176	0.98	115/312	60/149	55/163	0.16	94/263	50/125	44/138	0.32	125/337	68/161	57/176	0.01*	56/131	25/55	31/76	0.05	96/312	50/149	46/163	0.31
MSM (n = 337)	(92.6)	(92.5)	(92.6)	0.98	(36.8)	(40.3)	(33.7)	0.16	(35.7)	(40.0)	(31.9)	0.32	(37.1)	(42.2)	(32.3)	0.01*	(42.7)	(45.5)	(40.8)	0.05	(30.8)	(33.6)	(28.2)	0.31
CSW (n = 1367)	1340/1367	672/680	668/687	0.03*	519/1340	281/672	238/668	0.01*	257/931	152/481	105/450	0.01*	171/1367	96/680	75/687	0.09	872/1367	475/680	397/687	< 0.01**	687/1340	376/672	311/668	< 0.01**
CSW (n = 1367)	(98.0)	(98.8)	(97.2)	0.03*	(38.7)	(41.8)	(35.6)	0.01*	(27.6)	(31.6)	(23.3)	0.01*	(12.5)	(14.1)	(10.9)	0.09	(63.8)	(69.9)	(57.8)	< 0.01**	(51.3)	(55.9)	(46.6)	< 0.01**
CSW sub-groups
SSW (n = 594)	588/594	300/300	288/294	0.01*	242/588	128/300	114/288	0.23	112/380	152/481	48/186	0.58	56/594	33/300	23/294	0.11	403/594	223/300	180/294	< 0.01 **	354/588	195/300	159/288	0.02*
SSW (n = 594)	(98.9)	(100.0)	(98.0)	0.01*	(41.1)	(42.6)	(39.6)	0.23	(29.5)	(31.6)	(25.8)	0.58	(9.4)	(11.0)	(7.8)	0.11	(67.8)	(74.3)	(61.2)	< 0.01 **	(60.2)	(65.0)	(55.2)	0.02*
KSW (n = 599)	592/599	299/300	293/299	0.05	231/582	128/299	103/293	0.01*	109/414	70/224	39/140	0.03*	63/599	36/300	27/299	0.18	389/599	211/300	178/299	0.01*	284/592	155/299	129/293	0.06
KSW (n = 599)	(98.8)	(99.6)	(97.9)	0.05	(39.7)	(42.8)	(35.2)	0.01*	(26.3)	(31.3)	(27.9)	0.03*	(10.5)	(12.0)	(9.0)	0.18	(64.9)	(70.3)	(59.5)	0.01*	(47.9)	(51.8)	(44.0)	0.06

*Significant at p < 0.05; **Significant at p < 0.01; ***Significant at p < 0.001

Back to article page

ISSN: 1471-2458

Contact us

Submission enquiries: bmcpublichealth@biomedcentral.com
General enquiries: ORSupport@springernature.com